CML patient experience study on standard TKI therapy
Part of Blood & lymphatic, Cancer clinical trials.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have Philadelphia chromosome positive CML in chronic phase.
- You are taking one of these TKI medicines as your first or second line treatment: asciminib, bosutinib, dasatinib, imatinib, or nilotinib.
- You receive your care at a medical practice in the US or Puerto Rico.
- You agree to let the study access your anonymized medical records or claims data.
- You are not currently in a clinical trial that could change how your CML is managed.
- You are not taking a third or later line TKI, have a T315I mutation, are in treatment-free remission, or have had a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication for people with chronic myeloid leukemia (CML) who have already tried at least three other treatments without success or with side effects. The goal is to see if this new drug can help control the leukemia.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This trial tests a new combination treatment for people with chronic myeloid leukemia (CML) whose disease is resistant to or intolerant of current standard drugs. The goal is to see if the study drug works better when combined with another drug, and to check its safety.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
Hear when a new Chronic Myelogenous Leukemia - Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.